The financials
Cytokinetics, Incorporated by the numbers
Cytokinetics, Incorporated (CYTK) reported revenue of $29M in Q2 2026 (quarter ended June 30, 2026), down 57% from the same quarter a year earlier. That came with net loss of $199M. For the full year FY2025, revenue was $88M (+377% year on year) and net income −$785M. Its largest product in 2026-Q1 was License And Milestone at $12M, 62% of the disclosed total, just ahead of Net Product at 25%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $29M | $67M | −57% |
| Operating income | −$179M | −$112M | n/a |
| Net income | −$199M | −$134M | n/a |
| Diluted EPS | −$1.50 | −$1.12 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Milestone | $12M | 62% |
| Net Product | $4.8M | 25% |
| Collaboration | $2.6M | 14% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $19.4M (+900%)
Collaboration grew +67% year on year
Segment Latestquarter on quarteryear on year
- License And Milestone$11.9M$11.9MQoQ -year on year ---
- Net Product$4.8M$4.8MQoQ -year on year ---
- Collaboration$2.6M$2.6MQoQ +36%year on year +67%+36%+67%